Navigation Links
China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
Date:1/29/2008

-- The Approval Creates New Growth Opportunities for the Company -- Potentially Denotes a Positive Sign Related to the SFDA Drug Approval

Process

NEW YORK and HAIKOU, China, Jan. 29 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it has received approval from the Chinese State Food and Drug Administration (SFDA) for the production of generic Bumetanide injection which is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome by inducing dieresis.

Bumetanide is internationally recognized as one of the most effective diuretics and widely prescribed for cardiovascular diseases, kidney diseases, respiratory diseases, neurological diseases, and surgeries. It has replaced Furosemidum and other diuretic medications on the market because of its efficiency and safety. Bumetanide is on China's National Medical Reimbursement Insurance List thus allowing insured patients to receive reimbursement for the costs of injections. In China, medium size hospitals dispense on average 8,000 doses of Bumetanide per month.

"We are very pleased that we received approval of Bumetanide from the Chinese SFDA, a very important and positive milestone for our business which further diversifies and complements our core product portfolio," Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., commented. "We believe this favorable decision by the SFDA is a positive sign that the SFDA new drug approval process is coming back online. For this reason, we are optimistic that the additional drugs that are currently in our development pipeline for SFDA approval will be able to move through this process toward commercialization."

"Additionally, we are well positioned to take advantage of this new growth opportunity. This approval will enable China Pharma to immediately leverage our production capacity and extensive distribution network covering 30 provinces to start production and marketing of this new drug. We expect to begin Bumetanide production and recording of revenues in March 2008. We currently maintain the capacity to produce approximately $2 million of this product annually," concluded Ms. Li.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

Safe Harbor Statement:

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward- looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

Sophia Yu

China Pharma Holdings, Inc.

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

Alan Sheinwald

HC International, Inc.

Tel: +1-914-669-0222

Email: Alan.sheinwald@hcinternational.net


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Medical Technologies to Announce Financial Results for the Third Quarter Ended December 31, 2007 on February 28, 2008
2. China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Womens Health Issues
3. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
4. Knee Implant Market Booming in China
5. Chinas biotech industry: An Asian dragon is growing
6. Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China
7. China Sky One Medical Appoints Independent Auditor
8. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
9. MM2 Group Establishes New Venture for Sofgel Manufacture in China
10. China Shenghuo Pharmaceutical Holdings, Inc. to Launch 12Ways(R) Advertisement on CCTV in January 2008
11. Chinas Anti-Aging Revolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology: